|
    ORPH U.S.: Nasdaq

    Orphazyme A/S ADR

    ORPHUS
    After Hours
    Back To Top
    Last Updated: Jul 30, 2021 7:58 p.m. EDT Delayed quote

    $ 4.7500

    -0.03 -0.63%
    After Hours Volume: 11.45K
    Close Chg Chg %
    $4.7800 -0.0400 -0.83%
    Advanced Charting
    • $
    • %
    • Vol
    Volume: 679.62K 65 Day Avg: 11.68M
    6% vs Avg
    4.7200 Day Range 4.8700
    4.6000 52 Week Range 77.7700

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    ORPH Overview

    Performance

    5 Day
    • -9.47%
    1 Month
    • -33.70%
    3 Month
    • -49.26%
    YTD
    • -55.45%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 5 Full Ratings
    • Other News
    • Press Releases

    Orphazyme’s Massive Price Appreciation Won’t Be Captured Again

    on InvestorPlace.com

    Orphazyme A/S May Look Like a Long Shot, but Things Aren’t That Dire

    on InvestorPlace.com

    Despite FDA Disappointment, All Hope Isn’t Lost for Orphazyme

    on InvestorPlace.com

    ORPH Stock: The Big News That Has Red-Hot Orphazyme Gaining Today

    on InvestorPlace.com

    What Will the Stock Market Do Today? 3 Big Stories to Watch.

    on InvestorPlace.com

    Short Squeeze Stocks: CLOV, AEI and 3 Other Stocks Experts Think Are Ready to Pop

    on InvestorPlace.com

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

    on InvestorPlace.com

    Why Orphazyme Stock Skyrocketed 24.6% Today

    on Motley Fool

    ORPH Stock: Why Orphazyme Is Gaining Today Despite FDA Disappointment

    on InvestorPlace.com

    Assess Biotech Landscape Hazards Before Trading Orphazyme Stock

    on InvestorPlace.com

    Orphazyme: Unclear Path Ahead Merits a Downgrade

    on TipRanks.com

    This Is How You Could Have Anticipated Orphazyme's Implosion

    on Motley Fool

    Here's Why Orphazyme Stock Is Imploding Today

    on Motley Fool

    GEO Stock: Shares of Recent Reddit Play GEO Group Surge on CEO Buy-In

    on InvestorPlace.com

    What Will the Stock Market Do Today? 3 Big Stories to Watch.

    on InvestorPlace.com

    ORPH Stock: The FDA News That Has Orphazyme Plunging Today

    on InvestorPlace.com

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

    on InvestorPlace.com

    Orphazyme (ORPH) Share Price Rose By Almost 61%; What are the Catalysts?

    on TipRanks.com

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

    on InvestorPlace.com

    Here's Why Orphazyme Shares Rocketed Higher on Wednesday

    on Motley Fool

    Orphazyme A/S ADR

    Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.